Published in Law and Health Weekly, May 19th, 2007
MCHR1 represents a new biological target for treating obesity and is the subject of research programs at many major pharmaceutical companies. Neurogen believes its MCHR1 program may be the most advanced in the industry. NGD-4715 and other compounds in the Company's MCHR1 obesity program are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.